153
Participants
Start Date
June 2, 2021
Primary Completion Date
November 30, 2022
Study Completion Date
April 6, 2023
NOV-001
NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
NB1000S
A recombinant live biotherapeutic product.
NB2000P
A botanically derived polysaccharide.
Placebo
Placebo
Chesapeake Urology Associates, Hanover
Associated Urologists of North Carolina, Raleigh
Georgia Clinical Research, Lawrenceville
Advanced Urology Institute, Daytona Beach
Prohealth Research Center, Doral
Florida Urology Partners, Tampa
University of Alabama at Birmingham, Birmingham
AMR Knoxville, Knoxville
Knoxville Kidney Center, Knoxville
Clinical Research Solutions, Cleveland
University of Cincinnati, Cincinnati
Indiana University, Carmel
University of Iowa Hospitals and Clinics, Iowa City
Mayo Clinic, Rochester
Washington University, St. Louis, St Louis
Houston Metro Urology, Houston
Idaho Urologic Institute, Meridian
Mayo Clinic, Scottsdale
The Miriam Hospital, Providence
Alpha Recherche Clinique, Québec
Lead Sponsor
Novome Biotechnologies Inc
INDUSTRY